title: Neuronal peroxisome proliferator-activated receptor gamma signaling: regulation by mood-stabilizer valproate.
abstract: Valproate (Depakote) remains an effective medication for the prevention and treatment of seizures in epilepsy and of mood symptoms in bipolar disorder. Both of these disorders are severe and debilitating, and both warrant further medication options as well as a better understanding of the side effects associated with their current treatments. Although a number of molecular and cellular processes have been found to be altered by valproate, the medication's therapeutic mechanism has not been fully elucidated. In this paper, peroxisome proliferator-activated receptor (PPAR) signaling was examined to determine valproate's effects on this transcriptional regulatory system in neuronal tissue. PPAR signaling has been found to affect a number of biochemical processes, including lipid metabolism, cellular differentiation, insulin sensitivity, and cell survival. When primary neuronal cultures were treated with valproate, a significant decrease in PPARgamma signaling was observed. This effect was demonstrated through a change in nuclear quantities of PPARgamma receptor and decreased DNA binding of the receptor. Valproate also caused gene expression changes and a change to the peroxisome biochemistry consistent with a decrease of PPARgamma signaling. These biochemical changes may have functional consequences for either valproate's therapeutic mechanism or for its neurological side effects and merit further investigation.
authors.affiliation: Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Lan
authors.forename: Peixiong
authors.initials: P
authors.lastname: Yuan
authors.forename: Guang
authors.initials: G
authors.lastname: Chen
authors.forename: Husseini K
authors.initials: HK
authors.lastname: Manji
mesh_terms: D042962:Acyl-CoA Oxidase / Q000235:genetics / Q000378:metabolism; D000818:Animals; D018692:Antimanic Agents / Q000494:pharmacology*; D001714:Bipolar Disorder / Q000188:drug therapy / Q000378:metabolism; D002374:Catalase / Q000235:genetics / Q000378:metabolism; D004827:Epilepsy / Q000188:drug therapy / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects / Q000502:physiology; D008297:Male; D009474:Neurons / Q000187:drug effects* / Q000201:enzymology; D047495:PPAR gamma / Q000235:genetics / Q000378:metabolism*; D051381:Rats; D011921:Rats, Inbred WKY; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology; D014635:Valproic Acid / Q000494:pharmacology*
chemical_list: D018692:Antimanic Agents; D047495:PPAR gamma; D014635:Valproic Acid; D002374:Catalase; D042962:Acyl-CoA Oxidase